Updated report on origins of clinical trial participants

pharmafile | January 12, 2011 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

The European Medicines Agency has published an updated report detailing the geographical origins of patients included in clinical trials for Marketing Authorisations Applications. The report demonstrates 61% of patients in pivotal clinical trials from January 2005 to December 2009 are from countries outside of the EU, EEA and EFTA.

The information confirms the trend to truly ‘global’ studies and the advantages of tapping into a global patient population for clinical development.

Companies entering a new country for the first time may find the regulatory process quite daunting, however Wainwright Associates can help. Our consultants offer expertise in all areas of regulatory affairs and pharmacovigilance relating to medicines, medical devices and other healthcare products in all the major territories of the world. We have 400 consultants in the Wainwright Associates global network located in over 60 countries. All our advisors are independent and speak the local language and can not only help with local regulations in their country but also advise on current attitudes.

If you require assistance, please contact Wainwright Associates via email at enquiries@wainwrightassociates.co.uk or telephone 01628 530554.

www.wainwrightassociates.com

 

Related Content

No items found
The Gateway to Local Adoption Series

Latest content